Many myopathies and muscle loss disorders have been linked with increased TGFβ signaling [34] and hence, our findings identify KLF6 as a potential therapeutic target for such pathological conditions, as well as for cancers, such as embryonal rhabdomyosarcoma, where TGFβ promotes cell proliferation [35]. This evidence concerns the gene TGFB1 and myopathy.